AGC Biologics, today, announced a new partnership with Altheia Science. Through this partnership, Altheia Science will advance its development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing.
AGC Biologics is performing drug product development at its Milan facility using lentiviral vector (LVV) and autologous CD34+ hematopoietic stem and progenitor cell systems. The cells will be transduced using a highly efficient ex vivo lentiviral material to encode the human PD-L1 DNA.
“The AGC Biologics Milan site has a long-standing expertise in successfully developing stem cell-based gene therapies, from clinical testing up to commercialization,” said Paolo Rizzardi, Chief Executive Officer of Altheia Science. “We believe this partnership is key in supporting our gene therapy programs and making these innovative therapies available to patients.”
The AGC Biologics Milan facility has one of the strongest development and manufacturing track records in the global cell and gene industry, working…
Click here to view original post
